Background
==========

BAY 60-4552 is a direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO). In preclinical studies BAY 60-4552 exhibited potent vasorelaxing properties and end-organ protective effects. Secondary pulmonary hypertension is a determinant of morbidity and mortality in patients with biventricular heart failure (bivHF). Weassumed that BAY 60-4552 would improve cardiopulmonary hemodynamics by restoring functionality of the NO/sGC/cGMP pathway and be well tolerated in patients with bivHF.

Methods
=======

This study evaluated safety, tolerability and invasive hemodynamics of 1, 2.5, 5, 7.5 and 10 mg oral BAY 60-4552 in patients with bivHF (LVEF ≤ 45%, mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary capillary wedge pressure \[PCWP\] ≥ 18 mmHg).

Results
=======

31 male and 11 female patients (65 ± 11 years; BMI 27.4 ± 4.4) were included. Mean hemodynamic parameters at baseline were PCWP: 23.9 ± 4.5 mmHg; right atrial pressure (RAP): 10.6 ± 4.3 mmHg; mPAP: 35.7 ± 8 mmHg; systolic blood pressure (SBP): 119.2 ± 17.4 mmHg; systemic vascular resistance (SVR): 1721 ± 534 dyn•s•cm^-5^; heart rate (HR): 70.6 ± 11.2 bpm; and cardiac index (CI): 1.99 ± 0.48 L/min/m^2^. Table [1](#T1){ref-type="table"} summarizes peak changes in invasive hemodynamics aftersingle dosesof 2.5, 7.5 and 10 mg. No relevant HR increase was observed. BAY 60-4552 was safe and well tolerated with mild adverse events (asymptomatic hypotension, n = 1; transient facial flushing, n = 5; mild headache, n = 4). Pharmakokinetic parameters were linear and mean elimination half-life ranged between 14 -- 20 h.

###### 

Changes in hemodynamic parameters

                         2.5 mg (n = 7)             7.5 mg (n = 12)            10 mg (n = 12)
  ---------------------- -------------------------- -------------------------- --------------------------
  PCWP \[mmHg\]          -7.3 ± 2.8 \[-28 ± 10%\]   -8.4 ± 3.1 \[-36 ± 13%\]   -9.3 ± 2.5 \[-43 ± 11%\]
  MPAP \[mmHg\]          -8.9 ± 6.1 \[-22 ± 12%\]   -8.0 ± 3.3 \[-24 ± 9%\]    -7.3 ± 3.3 \[-23 ± 8%\]
  RAP \[mmHg\]           -3.1 ± 3.5 \[-26 ± 29%\]   -4.3 ± 1.9 \[-40 ± 15%\]   -4.0 ± 2.3 \[-39 ± 15%\]
  SVR \[dyn•s•cm^-5^\]   -378 ± 550 \[-15 ± 21%\]   -523 ± 293 \[-33 ± 15%\]   -546 ± 267 \[-31 ± 12%\]
  CI \[L/min/m^2^\]      +0.3 ± 0.3 \[+17 ± 22%\]   +0.6 ± 0.4 \[+31 ± 22%\]   +0.7 ± 0.5 \[+33 ± 25%\]

Changes from baseline (absolute and \[relative\] mean ± SD) of invasive hemodynamics after oral administration of 2.5, 7.5 and 10 mg BAY60-4552, p \< 0.05 (for each change from baseline).

Conclusion
==========

In patients with bivHF, oral administration of BAY 60-4552 was well tolerated and mediated a potent vasodilation. Biventricular pre- and afterload were improved, which resulted in a significant increase in cardiac index. These first clinical results with an oral sGC stimulator in patients with bivHF demonstrate the potential of this new therapeutic principle.
